Recent News

• 12.15.2025 - Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
• 12.11.2025 - Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
• 12.08.2025 - Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
• 12.01.2025 - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.12.2025 - Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
• 11.07.2025 - Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
• 11.03.2025 - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.30.2025 - Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
• 10.30.2025 - Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
• 10.20.2025 - Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Recent Filings

• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - 144 Report of proposed sale of securities
• 11.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 8-K Current report
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.30.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.16.2025 - 144 Report of proposed sale of securities
• 10.16.2025 - 4 Statement of changes in beneficial ownership of securities